EGFR activation promotes PD-L1 expression via Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway22 and inhibits its degradation via phosphorylation mediated by GSK3β8 in the extracellular part of PD-L1, contributing to cancer escape from anti-tumor immunity. The gene discussed is STAT3; the disease is neoplasm.